November 12, 2020 – Medtronic plc (Dublin, Ireland) launched InPen, integrated with real-time Guardian Connect CGM data. The company says InPen is the first and only FDA-cleared smart insulin pen on the market for people on multiple daily injections (MDI).
The integrated system now provides real-time glucose readings alongside insulin dose information giving users everything they need to manage their diabetes in one view. Rather than switching between apps, users have the ability to see all their information in real-time, in one view.
The integration of real-time CGM data into the smart insulin pen app is a result of the addition of Companion Medical’s InPen to the Medtronic portfolio, as of September 2020. The company says that the acquisition enables Medtronic to serve more people and offers a unique and expansive ecosystem of support across their diabetes journey.
The InPen app will continue to display information from other currently compatible CGM systems on a three-hour delay.